POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 10 Mar 2018
At a glance
- Drugs Talazoparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms POSITION
- 05 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 05 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 23 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.